Blog
RSS FeedPosted by Michael Wonder on 05 Jul 2020
Assessment of technical errors and validation processes in economic models submitted by the company for NICE technology appraisals
3 July 2020 - Economic models play a central role in the decision-making process of NICE. ...
Posted by Michael Wonder on 22 Feb 2019
Choosing a time horizon in cost and cost-effectiveness analyses
21 February 2019 - When designing a comparative outcomes or a cost-effectiveness analysis, the time horizon defining the duration of time ...
Posted by Michael Wonder on 20 Sep 2018
Using evidence from randomised controlled trials in economic models: what information is relevant and is there a minimum amount of sample data required to make decisions?
21 September 2018 - Evidence from randomised controlled trials is used to support regulatory approval and reimbursement decisions. ...
Posted by Michael Wonder on 11 Jul 2018
Challenges and methodologies in using progression free survival as a surrogate for overall survival in oncology
11 July 2018 - A primary outcome in oncology trials is overall survival. However, to estimate overall survival accurately requires ...
Posted by Michael Wonder on 07 Jun 2018
Takeda pioneers NICE’s new service for economic model review
7 June 2018 - NICE Scientific Advice (NSA) launched a new health economic model review service, PRIMA, in December 2017 and ...